Loss of function of MECP2 in Rett syndrome

Stable Identifier
R-HSA-9005891
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Loss of function mutations in methyl-CpG-binding protein 2 (MECP2), an epigenetic regulator of transcription, are the major cause of Rett syndrome, a neurodevelopmental disorder that affects 1 in 10,000-15,000 female births. The symptoms of Rett syndrome appear after 6-18 months of apparently normal postnatal development and include regression of acquired language and motor skills, stereotypic hand movements, intellectual disability, epileptic seizures and respiratory disturbances. Besides Rett syndrome, aberrant MECP2 expression is implicated as an underlying cause of other neuropsychiatric disorders (reviewed by Banerjee et al. 2012, Ebert and Greenberg 2013, Lyst and Bird 2015). Only functionally characterized MECP2 mutations are annotated. For a comprehensive list of MECP2 mutations reported in Rett syndrome, please refer to the RettBASE (http://mecp2.chw.edu.au), a database dedicated to curation of disease variants of MECP2, CDKL5 and FOXG1 in Rett syndrome (Krishnaraj et al. 2017).

Literature References
PubMed ID Title Journal Year
25732612 Rett syndrome: a complex disorder with simple roots

Lyst, MJ, Bird, A

Nat. Rev. Genet. 2015
22586411 Rett syndrome: genes, synapses, circuits, and therapeutics

Banerjee, A, Castro, J, Sur, M

Front Psychiatry 2012
  RettBASE

Christodoulou, J, Krishnaraj, R

   
28544139 RettBASE: Rett syndrome database update

Krishnaraj, R, Ho, G, Christodoulou, J

Hum. Mutat. 2017
23325215 Activity-dependent neuronal signalling and autism spectrum disorder

Ebert, DH, Greenberg, ME

Nature 2013
Participants
Participant Of
Disease
Name Identifier Synonyms
Rett syndrome 1206 Rett's disorder, cerebroatrophic hyperammonemia
Authored
Reviewed
Created